Abstract
The intravenous administration of a standard dose of conventional gadolinium-based contrast agents produces higher contrast between the tumor and normal brain at 3.0 Tesla (T) than at 1.5 T, which allows reducing the dose to half of the standard one to produce similar contrast at 3.0 T compared to 1.5 T. The assessment of cumulative triple-dose 3.0 T images obtained the best results in the detection of brain metastases compared to other sequences. The contrast agent dose for dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging at 3.0 T can be reduced to 0.1 mmol compared to 0.2 mmol at 1.5 T due to the increased susceptibility effects at higher magnetic field strengths. Contrast agent application makes susceptibility-weighted imaging (SWI) at 3.0 T clinically attractive, with an increase in spatial resolution within the same scan time. Whereas a double dose of conventional gadolinium-based contrast agents was optimal in SWI with respect to sensitivity and image quality, a standard dose of gadobenate dimeglumine, which has a two-fold higher T1-relaxivity in blood, produced the same effect. For MR-arthrography, optimized concentrations of gadolinium-based contrast agents are similar at 3.0 and 1.5 T. In summary, high field MRI requires the optimization of the contrast agent dose in different clinical applications.
Similar content being viewed by others
References
Frayne R, Goodyear BG, Dickhoff P et al (2003) Magnetic resonance imaging at 3.0 Tesla; Challenges and advantages in clinical neuroimaging. Invest Radiol 38:385–402
Schild H (2005) Klinische Hochfeld-MRT. Fortschr Röntgenstr 177:621–631
Bernstein MA, Huston J, Lin C et al (2001) High-resolution intracranial and cervical MRA at 3.0 T: technical considerations and initial experience. Magn Reson Med 46:955–962
Thulborn KR (1999) Clinical rationale for very high field (3.0 T) functional magnetic resonance imaging. Top Magn Reson Imag 10:37–50
Gonen O, Gruber S, Li BS et al (2001) Multivoxel 3D proton spectroscopy in the brain at 1.5 T versus 3.0 T: signal-to-noise ratio and resolution comparison. AJNR 22:1727–1731
Hunsche S, Moseley ME, Stoeter P, Hedehus M (2001) Diffusion-tensor MR imaging at 1.5 and 3.0 T: initial observations. Radiology 221:550–556
Rinck PA, Fischer HW, Van der Elst D et al (1988) Field-cycling relaxometry: medical applications. Radiology 168:843–849
Wood ML, Hardy PA (1993) Proton relaxation enhancement. J Magn Reson Imaging 3:149–156
Fernandez-Seara MA, Wehrli FW (2000) Postprocessing technique to correct for background gradients in image-based R* (2) measurements. Magn Reson Med 44:358–366
Wansapura JP, Holland SK, Dunn RS, Ball WS (1999) NMR relaxation times in the human brain at 3.0 Tesla. J Magn Reson Imaging 9:531–538
Elster AD (1994) Field-strength dependence of gadolinium enhancement: theory and implications. AJNR 15:1420–1423
Akeson P, Vikhoff B, Stahlberg F et al (1997) Brain lesion contrast in MR imaging: dependence of field strength and concentration of gadodiamide injection in patients and phantoms. Acta Radiol 38:14–18
Chang KH, Ra DG, Han MH et al (1994) Contrast enhancement of brain tumours at different MR field strengths. Comparison of 0.5 T and 2.0 T. AJNR 15:1413–1419
Haustein J, Laniado M, Niendorf H-P et al (1992) Administration of gadopenteate dimeglumine in MR imaging of intracranial tumours: dosage and field strength. AJNR 13:1199–1206
Nöbauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V et al (2002) Magnetic resonance imaging contrast enhancement of brain tumours at 3 Tesla versus 1.5 Tesla. Invest Radiol 37:114–119
Krautmacher C, Tschampa H, Born M, C et al (2003) MRI of contrast enhancing brain tumours at 3 Tesla versus 1.5 Tesla: first clinical results evaluating T1-weighted SE, FFE and MDEFT sequences. ECR, European Congress of Radiology 437
Martini N (1993) Operable lung cancer. CA Cancer J Clin 43(4):201–214
Healy ME, Hesselink JR, Press GA, Middleton MS (1987) Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 165:619–624
Yuh WT, Fisher DJ, Engelken JD et al (1991) MR evaluation of CNS tumours: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485–491
Runge VM, Kirsch JE, Burke VJ et al (1992) High-dose gadoteridol in MR imaging of intracranial neoplasmas. J Magn Reson Imaging 2:9–18
Ba-Ssalamah A, Noebauer-Huhmann IM, Pinker K et al (2003) The effect of contrast dose and field strength in the MR detection of brain metastases. Invest Radiol 38:414–421
Naganawa S, Koshikawa T, Nakamura T et al (2004) Comparison of flow artefacts between 2D-FLAIR and 3D-FLAIR sequences at 3 T. Eur Radiol 14:1901–1908
Parizel PM, Dijkstra HA, Geenen GP et al (1995) Low-field versus high-field MR imaging of the knee: a comparison of signal behaviour and diagnostic performance. Eur J Radiol 19:132–138
Schick F (2005) Whole-body MRI at high field: technical limits and clinical potential. Eur Radiol 15:946–959
Heiland S, Kreibich W, Reith W et al (1998) Comparison of echo-planar sequences for perfusion-weighted MRI: which is best? Neuroradiology 40:216–221
Manka Ch, Träber F, Gleseke J, Schild H, Kuhl C (2005) Three-demensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose. Eur Radiol 234:869–877
Flacke S, Urbach H, Folkers PJ et al (2000) Ultra-fast three-dimensional MR perfusion imaging of the entire brain in acute stroke assessment. J Magn Reson Imaging 11:250–259
Flacke S, Urbach H, Block W et al (2002) Perfusion and molecular diffusion-weighted MR imaging of the brain: in vivo assessment of tissue alteration in vertebral ischemia. Amino Acids 23:309–316
Essig M, Lodemann KP, LeHuu M, Schonberg SO, Hubener M, Van Kaick G (2002) Comparison of multihance and gadovist for cerebral MR perfusion imaging in healthy volunteers. Radiology 42:909–915
Liu G, Sobering G, Duyn J, Moonen CT (1993) A functional MRI technique combining principles of echo-shifting with a train of observations (PRESTO). Magn Reson Med 30:764–768
Van Gelderen P, Grandin C, Petrella JR, Moonen CT (2000) Rapid three-dimensional MR imaging method for tracking a bolus of contrast agent through the brain. Radiology 216:603–608
Duyn JH, Van Gelderen P, Barker P, Frank JA, Mattay VS, Moonen CT (1994) 3D bolus tracking with frequency-shifted BURST MRI. J Comput Assist Tomogr 18:680–687
Cavagna FM, Maggioni F, Castelli PM et al (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796
Tombach B, Benner T, Reimer P et al (2003) Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 verus 1.0 mol/l gadobutrol. Radiology 226:880–888
Reichenbach JR, Venkatesan R, Schillinger DJ et al (1997) Small vessels in the human brain: MR venography with deoxyhemoglobolin as an intrinsic contrast agent. Radiology 204(1):272–277
Reichenbach JR, Jonetz-Mentzel L, Fitzek C et al (2001) High-resolution blood oxygen-level dependent MR venography (HRBV): a new technique. Neuroradiology 43(5):364–369
Essig M, Reichenbach JR, Schad LR et al (1999) High-resolution MR venography of cerebral arteriovenous malformations. Magn Reson Imaging 17(19):1417–1425
Lee BC, Vo KD, Kido DK et al (1999) MR high-resolution blood oxygenation level-dependent venography of occult (low-flow) vascular lesions. AJNR 20(7):1239–1342
Tan IL, van Schijndel RA, Pouwels PJ et al (2000) MR venography of multiple sclerosis. AJNR 21(6):1039–1042
Reichenbach JR, Barth M, Haacke EM et al (2000) High resolution MR venography at 3.0 Tesla. J Comput Assist Tomogr 24:949–957
Novak V, Abduljalil A, Kangarlu A et al (2001) Intracranial ossifications and microangiopathy at 8 Tesla MRI. Magn Reson Imaging 19(8):1133–1137
Lin W, Mukherjee P, An H et al (1999) Improving high-resolution MR bold venograhic imaging using at T1 reducing contrast agent. J Magn Reson Imaging 10(2):118–123
Barth M, Nöbauer-Huhmann IM, Reichenbach JR et al (2003)High resolution three-dimensional contrast-enhanced blood oxygenation level-dependent magnetic resonance venography of brain tumours at 3 Tesla: First clinical experience and comparison with 1.5 Tesla. Invest Radiol 38:408–413
Nöbauer-Huhmann I, Tratting S, Pinker K, Barth M, Mlynarik V, Beisteiner R, Weber M, Witoszynskyj S, Raucher A, Reichenbach J, Ba-Ssalamah A (in press) Contrast-enhanced high resolution susceptibility weighted MR imaging (CE-SWI) of brain: Dosage dependent optimization at 3 Tesla and 1.5 Tesla in healthy volunteers. Department of Radiology. Invest Radiol
Tynninen O, Aronen HJ, Ruhala M et al (1999) MRI enhancement and microvascular density in gliomas. Correlation with tumour cell proliferation. Invest Radiol 34(6):427–434
Henry RG, Vigneron DB, Fischbein NJ et al (2000) Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR 21(2):357–366
Kuperman V, River JN, Lewis MZ et al (1995) Changes in T2*-weighted images during hyperoxia differentiate tumours from normal tissue. Magn Reson Med 33(3):318–325
Karczmar GS, Kuperman VY, River NJ et al (1994) Magnetic resonance measurement of response to hyperoxia differentiates tumours from normal tissue and may be sensitive to oxygen consumption. Invest Radiol 29(Suppl 2):161–163
Robinson SP, Howe FA, Griffiths JR (1995) Noninvasive monitoring of carbogen-induced changes in tumour blood flow and oxygenation by functional magnetic resonance imaging. Int J Radiat Oncol Biol Phys 33(4):855–859
Robinson SP, Howe FA, Rodrigues LM et al (1998) Magnetic resonance imaging techniques for monitoring changes in tumour oxygenation and blood flow. Semin Radiat Oncol 8(3):197–207
Steinbach LS, Palmer WE, Schweitzer ME (2002) Special focus session: MR arthrography. Radiographics 22:1223–1246
Chung CB, Corrente L, Resnick D (2004) MR arthrography of the shoulder. Magn Reson Imaging Clin N Am 12:25–38
Czerny C, Oschatz E, Neuhold A, Tschauner C, Hofmann S, Kramer J (2002) MR Arthrographie des Hüftgelenkes. Radiologe 42:451–456
Waldt S, Burkart A, Lange P, Imhoff AB, Rummeny EJ, Wortler K (2004) Diagnostic performance of MR arthorgraphy in the assessment of superior labral anterosposterior lesions of the shoulder. AJR 182:1271–1278
Grainger AJ, Elliott JM, Campbell RS, Tirman PF, Steinbach LS, Genant HK (2000). Direct MR arthrography: a review of current use. Clin Radiol 55:163–176
Masi J, Newitt D, A.Sell Ch, Daldrup-Link H, Steinbach L, Majumdar S, Link T (2005) Optimization of gadodiamide concentration for MR arthrography at 3 T. AJR 184:1754–1761
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trattnig, S., Pinker, K., Ba-Ssalamah, A. et al. The optimal use of contrast agents at high field MRI. Eur Radiol 16, 1280–1287 (2006). https://doi.org/10.1007/s00330-006-0154-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-006-0154-0